ATS Medical, Inc.

ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac surgery by developing, manufacturing, and marketing innovative products and services for the treatment of structural heart disease. Founded in 1991, the company focuses on two distinct yet operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias. Initially, ATS Medical aimed to develop the ATS Open Pivot® Heart Valve as a new mechanical heart valve standard of care. The Open Pivot heart valve has become the preferred mechanical heart valve in many markets globally and is the fastest-growing mechanical prosthesis. Expanding its product offerings, the ATS 3f® brand includes an innovative tissue heart valve portfolio to address conventional open surgery requirements and the demand for less invasive sutureless-based procedures. Additionally, the company offers the ATS Simulus® annuloplasty product line to repair a patient's native heart valve as an alternative to replacement. In the field of surgical cryoablation of cardiac arrhythmias, ATS Medical provides the ATS CryoMaze(TM) products, catering to the treatment of patients suffering from cardiac arrhythmias, the largest and fastest-growing form of structural heart disease in populations over 60 years of age. In December 2008, ATS Medical secured a $20.00M Private Equity Round investment from Essex Woodlands Healthcare Partners. This investment signifies a vote of confidence in the company's innovative products and services aimed at advancing cardiac surgery standards, ultimately contributing to improved patient outcomes within the Health Care industry.